SL1716
/ SenlangBio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 04, 2025
Nanobody-based CD19/CD20 bispecific CAR-T achieves durable remissions in r/r NHL patients
(ASH 2025)
- "Among treatment-refractory cases, 3 had prior CAR-T exposure,including 1 case of CD19/CD22 CAR-T and 2 case of CD19 CAR-T therapy, all with subsequent relapse.Following lymphodepletion, all patients received SL1716 (CD19/CD20 bispecific CAR-T) at 4×106 cells/kg,with 100% manufacturing success rate. SL1716, a nanobody-based CD19/CD20 bispecific CAR-T cell therapy, demonstrates afavorable safety profile and durable clinical efficacy in patients with r/r NHL. These promising resultssupport its potential as an effective treatment option for this high-risk patient population."
Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • CD20 • CD22
November 28, 2025
Big Announcement | Senlang Biotechnology’s 6 Cutting-Edge Achievements to be Showcased at ASH2025 [Google translation]
(Senlang Biotech Press Release)
- "The company will officially release six of its latest clinical research findings during the conference, including its core products: CD7-targeted SENL101, CD19/BCMA dual-targeted SL1703, CD19/CD20 dual-targeted SL1716, and BCMA/GPRC5D dual-targeted SL0439."
Clinical data • Multiple Myeloma • Non-Hodgkin’s Lymphoma
1 to 2
Of
2
Go to page
1